SCHEDULE 13G/A: Walleye Capital Discloses 4.82% Stake in Unicycive Therapeutics via Amended SEC Filing

Walleye Capital LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 4.82% of Unicycive Therapeutics, Inc.'s common stock as of December 31, 2024.

Summary

• Walleye Capital LLC, a Minnesota limited liability company, filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in UNICYCIVE THERAPEUTICS, INC.
• As of December 31, 2024, Walleye Capital LLC beneficially owned 5,000,000 shares of Unicycive Therapeutics' common stock.
• This ownership represents 4.82% of the total class of securities.
• Walleye Capital LLC holds sole voting power and sole dispositive power over all 5,000,000 shares.
• The filing indicates that Walleye Capital LLC is an investment adviser (IA) and that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently suggest a positive or negative sentiment regarding the company's performance or outlook.

Positives

• The filing indicates that Walleye Capital LLC is an investment adviser, suggesting a professional, institutional investment in the company.
• The acquisition of shares was stated to be in the ordinary course of business, implying a non-activist, passive investment approach.

Negatives

• No specific negative information regarding Unicycive Therapeutics, Inc. or Walleye Capital LLC is contained within this beneficial ownership report.

Risks

• No specific risks related to the issuer's operations, financial health, or future prospects are detailed in this beneficial ownership report, as it is solely a disclosure of share ownership.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Unicycive Therapeutics, Inc.'s future performance or strategic direction.

Industry Context

This filing is a standard disclosure by an institutional investor (Walleye Capital LLC, an investment adviser) regarding its stake in a publicly traded company, Unicycive Therapeutics, Inc., which operates in the biotechnology or pharmaceutical sector. Such filings are common and provide transparency on significant ownership positions within various industries.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which may be viewed as a vote of confidence, although the stake is below the 5% threshold for initial Schedule 13G filing and is an amendment.

Key Dates

Keywords

Unicycive Therapeutics, Walleye Capital, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Adviser, Biotechnology, Pharmaceuticals